Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 454-458

  Ozawa, Shogo ^a   Hamada, Masashi ^a,b   Murayama, Norie ^a   Nakajima, Yukiko ^a   Kaniwa, Nahoko ^a   Matsumoto, Yoshiaki ^b   Fukuoka, Masamichi ^b   Sawada, Jun Ichi ^a   Ohno, Yasuo ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; CYP2A6; Doxifluridine; Tegafur; Thymidine phosphorylase

Indexed keywords

COUMARIN 7 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 3A4; DOXIFLURIDINE; DRUG METABOLITE; FLUOROURACIL; PHENACETIN O DEETHYLASE; PRODRUG; TEGAFUR; THYMIDINE PHOSPHORYLASE;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CYTOSOL; LIVER MICROSOME; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; FLOXURIDINE; FLUOROURACIL; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID HYDROXYLASES; TEGAFUR; THYMIDINE PHOSPHORYLASE;

EID: 0036453859     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0528-1     Document Type: Article

References (16)

1. Abe T, Kawai K, Sawai K, Misawa S, Takino T, Okuda K, Ohgawara Y (1978) Clinico-pharmacological studies on futraful granule. Vol 1: Basic experiments - Bioavailability. Gan To Kagaku Ryoho 5:747
2. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210
3. Cao S, Frank C, Shirasaka T, Rustum YM (1995) 5-Fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1:839
4. El Sayed YM, Sadee W (1983) Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) to 5-fluoro-uracil by soluble enzymes. Cancer Res 43:4039
5. Hara Y (1984) 5′-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues. Gan To Kagaku Ryoho 11:2133
6. Hara Y, Kono A, Tanaka M (1984) Measurement of 5′-deoxy-5-fluorouridine (5′-DFUR) by means of high performance liquid chromatography and studies on pharmacokinetics of 5′-DFUR and 5-fluorouracil by oral and intravenous administration. Gan To Kagaku Ryoho 11:2261
7. Haraguchi M, Furukawa T, Sumizawa T, Akiyama S-I (1993) Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 53:5680
8. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6:4409
9. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T (2000) Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorourcil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 28:1457
10. Komatsu T, Yamazaki H, Shimada, N, Nagayama S, Kawaguchi Y, Nakajima M, Yokoi T (2001) Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Clin Cancer Res 7:675
11. Lamont EB, Schilsky RL (l999) The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 5:2289
12. Meropol NJ (1998) Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 34:1509
13. Murayama N, Sai K, Nakajima Y, Kaniwa N, Ozawa S, Ohno Y, Sawada J (2001) Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res 92:524
14. Reece PA, Olver IN, Morris RG, Bishop JF, Guentert TW, Hill HS, Hillcoat BL (1990) Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion. Cancer Chemother Pharmacol 25:274
15. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, Danenberg PV (1984) Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44:4144
16. Spiegelman, S, Sawyer R, Nayak R, Ritzi E, Stolfi R, Martin D (1980) Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci U S A 77:4966